NCT03514420View on ClinicalTrials.gov

Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)

PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

June 15, 2018

Primary Completion Date

July 30, 2019

Study Completion Date

August 21, 2019

Conditions
Familial Partial Lipodystrophy
Interventions
DRUG

AKCEA-ANGPTL3-LRx

AKCEA-ANGPTL3-LRx solution for SC injection.

Trial Locations (1)

48105

Clinical Site, Ann Arbor

Sponsors

Lead Sponsor

Akcea Therapeutics
All Listed Sponsors
collaborator

Ionis Pharmaceuticals, Inc.

INDUSTRY

lead

Akcea Therapeutics

INDUSTRY